Drug regulators want to let drugmakers test Alzheimer’s disease treatments on patients years before the disease shows outward signs, and could approve the therapies based on subtle biological signals rather than proof they alleviate symptoms.The Food and Drug Administration proposal will open new paths for drugmakers after repeated failures from companies that include Pfizer, Eli Lilly and Merck.It also poses a scientific challenge.